A federal appeals court reinstated a paused Oregon law meant to ensure transparency behind rising prescription drug prices after a legal challenge claimed it infringed on the property and free speech rights of pharmaceutical companies.

In a 2-1 decision on Tuesday, the 9th Circuit Court of Appeals reversed a February 2024 ruling by U.S. District Court Judge Michael Mosman, who suspended new rules passed in a 2018 Oregon law — House Bill 4005 — that require drug manufacturers to submit annual price reports on increasingly expensive prescription drugs costing more than $100 for a month’s supply. Under the law, the Oregon Department of Consumer and Business Services required pharmaceutical companies to provide “a narrative description and explanation of all major financial and nonfin

See Full Page